Skip to results
Modify your search
NARROW
1-12 of 12
Authors: Daniel Podzamczer
Journal Article
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens Free
Journal of Antimicrobial Chemotherapy, Volume 78, Issue 11, November 2023, Pages 2696–2701, https://doi.org/10.1093/jac/dkad285
Published: 19 September 2023
Journal Article
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study Free
Journal of Antimicrobial Chemotherapy, Volume 77, Issue 7, July 2022, Pages 1980–1988, https://doi.org/10.1093/jac/dkac117
Published: 13 April 2022
Journal Article
Acute inflammatory demyelinating polyneuropathy following interruption of antiretroviral treatment and HIV rebound Free
Journal of Antimicrobial Chemotherapy, Volume 75, Issue 5, May 2020, Pages 1356–1357, https://doi.org/10.1093/jac/dkz573
Published: 30 January 2020
Journal Article
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients Free
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 12, 1 December 2016, Pages 3510–3514, https://doi.org/10.1093/jac/dkw347
Published: 02 September 2016
Journal Article
Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial Free
Journal of Antimicrobial Chemotherapy, Volume 71, Issue 5, May 2016, Pages 1346–1351, https://doi.org/10.1093/jac/dkv461
Published: 23 January 2016
Journal Article
EDITOR'S CHOICE
Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status Free
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 12, December 2015, Pages 3332–3338, https://doi.org/10.1093/jac/dkv272
Published: 25 September 2015
Journal Article
Antiviral activity and CSF concentrations of 600/100 mg of darunavir/ritonavir once daily in HIV-1 patients with plasma viral suppression Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 5, May 2015, Pages 1513–1516, https://doi.org/10.1093/jac/dku558
Published: 20 January 2015
Journal Article
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 4, April 2015, Pages 1130–1138, https://doi.org/10.1093/jac/dku501
Published: 23 December 2014
Journal Article
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial Get access
Journal of Antimicrobial Chemotherapy, Volume 70, Issue 4, April 2015, Pages 1139–1145, https://doi.org/10.1093/jac/dku516
Published: 18 December 2014
Journal Article
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group Get access
Journal of Antimicrobial Chemotherapy, Volume 69, Issue 5, May 2014, Pages 1390–1396, https://doi.org/10.1093/jac/dkt517
Published: 10 January 2014
Journal Article
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients Get access
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 10, October 2012, Pages 2479–2486, https://doi.org/10.1093/jac/dks227
Published: 22 June 2012
Journal Article
Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen Get access
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 6, June 2012, Pages 1453–1458, https://doi.org/10.1093/jac/dks057
Published: 29 February 2012
